P3.22: EFFECT OF TISSUE TRANSGLUTAMINASE (TG2) ON CARDIAC AND VASCULAR FUNCTION IN YOUNG TG2 KNOCKOUT MICE

K.D. Viegas, M. Butlin, A.P. Avolio


To link to this article: https://doi.org/10.1016/j.artres.2012.09.148

Published online: 21 December 2019
Modulation of venous capacitance may be an important effect of baroreceptor activation in hypertension and heart failure.

* Wright CI et al., Can J Cardiol 2004; 20:1127.

P3.22
EFFECT OF TISSUE TRANSGlutaminase (TG2) ON CARDIAC AND VASCULAR FUNCTION IN YOUNG TG2 KNOCKOUT MICE

K. D. Viegas, M. Butlin, A. P. Avolio
Macquarie University, Sydney, Australia

Background: Structural changes of the arterial wall are associated with increased arterial stiffness and hypertension. Tissue transglutaminase (TG2), an enzyme ubiquitously expressed in the vasculature, forms stable crosslinks between extracellular matrix proteins, including collagen. Due to its role in small artery remodelling, calcification and atherosclerosis, TG2 has been implicated in cardiovascular disease. The aim of this study was to compare parameters of cardiac and vascular function between TG2 knockout mice and wild-type littermates.

Methods: Male TG2−/− (n = 4) and TG2+/+ (n = 4) mice, aged 16 weeks, were anaesthetized with isoflurane. Aortic pressure was recorded with a 1.2 F high fidelity sensor via the left carotid artery. Mean and pulse pressure and augmentation index were determined from the pressure signal; baroreflex sensitivity computed from directional changes of systolic pressure and interbeat interval (ECG), and aortic pulse transit time from the R wave to foot of the aortic pulse. Ventricular weight was expressed as percentage of total body weight.

Results: TG2−/− mice showed significant differences only in relative ventricular weight compared to wild-type controls (Table).

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Wild-type</th>
<th>TG2−/−</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart rate (bpm)</td>
<td>619 ± 31</td>
<td>639 ± 26</td>
</tr>
<tr>
<td>Ventricular/body weight (%)</td>
<td>0.39 ± 0.016</td>
<td>0.44 ± 0.011</td>
</tr>
<tr>
<td>Mean arterial pressure (mmHg)</td>
<td>76.5 ± 1.1</td>
<td>72.1 ± 4.2</td>
</tr>
<tr>
<td>Pulse pressure (mmHg)</td>
<td>30.4 ± 0.40</td>
<td>28.1 ± 1.1</td>
</tr>
<tr>
<td>Augmentation index (%)</td>
<td>20.0 ± 1.9</td>
<td>18.0 ± 1.8</td>
</tr>
<tr>
<td>Baroreflex sensitivity (ms/mmHg)</td>
<td>2.04 ± 0.72</td>
<td>2.17 ± 0.55</td>
</tr>
<tr>
<td>ECG - aortic pulse delay (ms)</td>
<td>15.43 ± 0.71</td>
<td>14.80 ± 1.9</td>
</tr>
</tbody>
</table>

*p < 0.05

Conclusion: Although findings suggest a tendency for increased ventricular mass, TG2 does not influence other baseline cardiovascular parameters in young healthy mice. This is consistent with TG2 activity, which is modulated by Ca2+ and endothelial nitric oxide, being generally increased in inflammation and ageing. However, this study lays the ground work for future experiments in which inflammation or endothelial dysfunction will be induced, whereby TG2−/− mice would be expected to be protected from associated increase in vascular dysfunction and stiffness.

P4.01
PROXIMAL AND DISTAL AORTIC STIFFNESS AND CARDIAC FUNCTION IN YOUNG WOMEN

M. Banerjee 1,8, K. Khan 1,8, J. Corr 3,4, F. Khan 1,8, A. Vyas 1,8, K. Cruickshank 1,8
1Cardiovascular Research Group, University of Manchester, Manchester, United Kingdom
2Department of Cardiology, Wythenshawe Hospital, Manchester, United Kingdom
3Department of Cardiology, Manchester Royal Infirmary, Manchester, United Kingdom
4Department of Cardiovascular Medicine & Nutrition, King’s College, London, United Kingdom
5Cumbria Diabetes, Cumbria Partnership NHS Foundation Trust, Barrow in Furness, United Kingdom

Introduction: Diabetes and Hypertension affect cardiovascular structure and function. We investigated the relationship between large artery structure (ascending aortic intima-medial thickness - aaIMT), stiffness (ascending aortic distensibility-AAD & aortic pulse wave velocity-aPWV) and other cardiac structure and functional parameters by transthoracic echocardiogram (TTE) in a group of young pre-menopausal women without any cardiac disorder.

Patients and Methods: 83 women (age 35.8 years, 95% CI 34.7-36.8) underwent anthropometric, biochemical assessments, TTE and aPWV measurements. The aAIMT was measured by 2-D mode by parasternal long axis view. AAD was computed using measurements of aortic root diameter in systole and diastole and aPWV by Doppler US technique over descending aorta and thoraco-abdominal aorta between the origin of left subclavian artery and the bifurcation of the aorta.

Results: There was correlation between LV-isovolumic relaxation time and AAD (r = 0.336; p = 0.03) but not with aPWV. There was no relation between LV posterior wall thickness and aAIMT. After adjustment for age, body mass index, smoking history, day in menstrual cycle, systolic velocity time integral and total cholesterol only diastolic blood pressure was independently related to AAD (β: -0.18; 95% CI: -0.029 to -0.007; p = 0.001) and to aPWV (β: 0.082; 0.027 to 0.138; p = 0.004). Fasting plasma glucose influenced AAD (β: -0.212; -0.407 to -0.018; p = 0.033) but not aPWV.

Conclusion: In young women, without overt diabetes, hypertension or pre-existing cardiovascular disease, proximal but not distal aortic stiffness was related to LV stiffness, in part influenced by BP, while glycaemia influenced only the proximal aortic stiffness independent of LV systolic function.

P4.02
ASSESSING VENTRICULAR-VASCULAR INTERACTIONS NON-INVASIVELY IN HEALTHY ADOLESCENTS

The Hospital for Sick Children, Toronto, Canada

Withdrawn by the author.

P4.03
ORAL Lycopene SUPPLEMENTATION IMPROVES ENDOTHELIAL FUNCTION IN PATIENTS WITH CARDIOVASCULAR DISEASE: A RANDOMISED CONTROLLED TRIAL

P. R. Gajendragadkar 1, A. Hubsch 1, K. Mäki-Petäjä 1, M. Serg 2, I. B. Wilkinson 1, J. Cheriyan 1
1Department of Clinical Pharmacology, University of Cambridge, Cambridge, United Kingdom
2Department of Cardiology, University of Tartu, Tartu, Estonia

Introduction: Lycopene is a potent antioxidant and carotenoid in the ‘Mediterranean diet’. Plasma and adipose lycopene concentrations have previously been inversely correlated with cardiovascular disease (CVD) risk. We hypothesised that a standardised preparation of lycopene would improve endothelial function.

Methods: 36 healthy volunteers (HV) and 36 stable CVD patients on statins were randomised unequally (2:1) to either 7 mg lycopene or placebo daily for 2 months (NCT01100385). Forearm blood flow responses to intra-arterial infusions of acetylcholine, (endothelium-dependent vasodilatation,EDV); sodium nitroprusside (endothelium-independent vasodilatation,EDIV); and N G-monomethyl-L-arginine (measuring basal nitric oxide,NO) were measured using venous plethysmography.

Results: At baseline, both groups were similar in age, BP and hs-CRP but the CVD group had a lower LDL (2.4 ± 0.6 vs. 3.6 ± 0.9 mmol/L, P = 0.001). The CVD group had impaired EDV to ACh compared with HV (30% lower; 95% CI: -45, -10, P = 0.008). Lycopene improved EDV in CVD patients by 53% (95% CI: -9, +93, P = 0.03 vs. placebo) independent of changes in EDIV or basal NO. Lycopene did not change EDIV, EDV or basal NO in HV. Home blood pressure, LDL, HDL and hs-CRP levels were unchanged in both groups. A post-hoc analysis demonstrated that lycopene treatment improved EDV in CVD patients towards HV levels at baseline (3% lower; 95% CI: -30, +30, P = 0.85), suggesting normalization of vascular function.

Conclusion: Lycopene supplementation improves endothelial function in CVD patients but not HV, and may require further investigation in larger outcome studies.